Rafael Carrion, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.4%), education and travel and lodging — rather than concentrated in one kind of arrangement. Coloplast accounts for 76.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $74,725 and has fallen 64.8% since, to $26,333 in 2025. Among urology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 651 payments — averaging $367.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$183K
- Endo Pharmaceuticals Inc.$37K
- Rigicon,inc.$11K
- Boston Scientific$4K
- Endo USA, Inc.$798
- Baxter Healthcare$761
- plus $2K from 20 others
Across 25 payments — averaging $8228.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$206K
What the payments were for
- Consulting fees$92,05038%
- Speaking & faculty fees$21,2259%
- Travel & lodging$28,77212%
- Food & beverage$27,60712%
- Education$69,86729%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 454 | $183,489 |
| Endo Pharmaceuticals Inc. | 56 | $36,992 |
| Rigicon,inc. | 21 | $10,823 |
| Boston Scientific | 54 | $4,162 |
| Endo USA, Inc. | 13 | $798 |
| Baxter Healthcare | 9 | $761 |
| Procept Biorobotics Corporation | 13 | $558 |
| Axonics, Inc. | 4 | $245 |
| Urogen Pharma, Inc. | 5 | $210 |
| Teleflex LLC | 1 | $175 |
| Innovation Technologies Inc | 1 | $169 |
| Johnson & Johnson | 1 | $133 |
| Travere Therapeutics, Inc. | 1 | $122 |
| Cook Medical LLC | 3 | $121 |
| Therapeuticsmd, Inc. | 1 | $110 |
| Antares Pharma, Inc. | 2 | $100 |
| Laborie Medical Technologies Corp. | 1 | $99 |
| Ambu Inc. | 2 | $94 |
| Astellas Pharma US Inc | 1 | $82 |
| Acerus Pharmaceuticals Corporation | 1 | $76 |
| Dentsply IH AB | 2 | $73 |
| Bayer | 1 | $50 |
| Organogenesis Inc. | 1 | $24 |
| BD | 1 | $24 |
| KARL Storz Endoscopy-america | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$175,639
- XIAFLEX$36,159
- RIGI10 MALLEABLE PENILE PROSTHESIS$10,052
- GENERAL ERECTILE DYSFUNCTION$1,500
- ALTIS$497
- FLOSEAL$393
- AMS$375
- TISSEEL$290
- AquaBeam Robotic System$284
- AMS 700$283
- AVEED$260
- SPEEDICATH$242
- UroLift$175
- Irrisept$169
- GENERAL - THERAPIES$164
- Spectra$147
- Erleada$133
- AKEEGA$133
- JELMYTO$125
- (815) Thiola$122
How this compares
$239,521 in reported general payments places this provider in the 95th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiaflexCollagenase Clostridium Hist. | 19 | $250,698 |
| Pentoxifylline | 221 | $4,857 |
| Tamsulosin Hcl | 259 | $3,533 |
| Tadalafil | 17 | $2,485 |
| Silodosin | 16 | $1,859 |
| Testosterone Cypionate | 41 | $1,656 |
| Sildenafil Citrate | 11 | $1,589 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 42 | $1,082 |
| Finasteride | 28 | $392 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $172 |
| Ciprofloxacin Hcl | 16 | $128 |
| Anastrozole | 14 | $81 |
| Meloxicam | 20 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Endo Pharmaceuticals Inc.Xiaflex | $36,992 | $250,69819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 urology providers in Florida.
Other urology in Tampa
- Raviender BukkapatnamTampa$115K
- Trushar PatelTampa$88K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.